



# Nipro Medical UK Ltd Carbon Reduction plan

**Prepared by:** Nipro Medical Europe  
**Signed off:** Serge Kemps, CEO Nipro Medical Europe  
**Version:** 1.0  
**Date:** February 2026  
**Applies to:** UK public sector procurement (PPN006)

---

# 1. Commitment to Achieving Net-Zero.

Nipro Medical Europe is committed to achieving net zero greenhouse gas emissions by 2045 across its operations, in line with UK Government targets under the *Climate Change Act 2008 (as amended in 2019)* and the NHS Net Zero Supplier Roadmap.

As part of the Nipro Group's global sustainability strategy, Nipro Medical Europe—together with Nipro Medical UK Ltd—aligns with the Group's long-term ambition to reach net zero for Scopes 1 and 2 by 2045, and will establish time-bound Scope 3 reduction targets and pathways in a later phase of our decarbonisation plan.

Nipro Corporation (the Group) recognises climate change as a material business risk and a critical factor in long-term business continuity. The Group continuously monitors greenhouse gas (GHG) emissions as a key risk indicator and integrates climate considerations into strategic planning, investment decisions, and operational management.

## 2. Baseline Emission Footprint

### 2.1. Baseline Year: 2021

Baseline emissions are a record of the greenhouse gases produced prior to the introduction of any strategies to reduce emissions and serve as the reference point against which all reductions are measured.

### 2.2. Method of calculation

The emissions are calculated in accordance with the GHG Protocol Corporate Accounting and Reporting Standard ([ghgprotocol.org/corporate-standard](https://ghgprotocol.org/corporate-standard)). Scope 1 and Scope 2 emissions are calculated using international GHG emission factors and emissions are calculated for UK by using UK Government DEFRA/DESNZ GHG Conversion Factors for Company Reporting for the relevant year. For Scope 2, the location-based method is applied. Emission factors are updated annually to reflect changes in the electricity grid mix.

Scope 3 categories are identified and quantified in line with the GHG Protocol Corporate Value Chain (Scope 3) Standard ([ghgprotocol.org/standards/scope-3-standard](https://ghgprotocol.org/standards/scope-3-standard)). Where primary, activity-level data is not yet available, spend-based screening is used as an interim approach, consistent with common practice in the medical devices and healthcare sector.

In more details this Carbon reduction plan covers our entire value chain, including:

#### Scope 1 (Direct Emissions):

- Natural gas and fuel consumption in manufacturing facilities
- Fleet vehicles (owned and leased)
- Refrigerant emissions from facilities



**Scope 2 (Indirect Emissions - Energy):**

- Purchased electricity (location-based and market-based methods per GHG Protocol guidance)
- District heating and cooling

**Scope 3 (Value Chain Emissions): under development**

- Purchased goods and services (raw materials, components, packaging, services)
- Capital goods and capital investments
- Fuels and energy related activities (not included in Scope 1&2)
- Upstream and downstream transportation and distribution
- Waste generated in operations
- Business travel and employee commuting
- Upstream leased assets
- Processing of sold products
- Use of sold products (power consumption during customer operations)
- End-of-life treatment of sold product
- Downstream leased assets

Geographic Scope: All owned manufacturing and distribution facilities globally.

**2.3. Emission data**

The following table reports Scope 1, 2, and 3 emissions for Nipro Medical Europe NV's operations. Note: 2024 being our latest year with reported figure and we are in the process of obtaining 2025':

<b>Emissions Category</b>	<b>Baseline (tCO<sub>2</sub>e) 2021</b>	<b>Current (tCO<sub>2</sub>e) [2024]</b>	<b>Notes</b>
Scope 1 – Direct	225	150	Natural gas, diesel, fleet, refrigerant fugitives
Scope 2 – Location-based	1,031	1,074	IEA /ecoinvent
Scope 3 :			
Scope 3 – Cat. 1: Purchased goods & services		101,001	Activity data based & Spend based
Scope 3 – Cat. 2: Capital goods		23	Spend-based screening
Scope 3 – Cat. 3: Fuel & energy activities		91	Derived from Scope 1 & 2 data



Scope 3 – Cat. 4: Upstream transport		15,750	Inbound & outbound freight & warehouse.
Scope 3 – Cat. 5: Waste in operations		149	Primary waste data
Scope 3 – Cat. 6: Business travel		693	Travel provider data
Scope 3 – Cat. 7: Employee commuting		801	Staff survey
Scope 3 – Cat. 8: Upstream leased assets		3,399	Spend based
Scope 3 – Cat. 9: Downstream T&D		9,500	Activity based.
Scope 3 – Cat. 11: Use of sold products		43,508	Estimated from product energy data
Scope 3 – Cat. 12: End-of-life treatment		205	Sales & packaging data
Scope 3 – Cat. 13: Downstream leased assets		6,988	Estimated from product energy data
Cats. 10, 14–15			Not relevant to Nipro Medical Europe's activities
<b>TOTAL EMISSIONS</b>	<b>1,256</b>	<b>182,582</b>	

Emissions are reported in **tCO<sub>2</sub>e** and include the seven Kyoto gases: CO<sub>2</sub>, CH<sub>4</sub>, N<sub>2</sub>O, HFCs, PFCs, SF<sub>6</sub> and NF<sub>3</sub>.

## 2.4. Verification of information

Annual third-party verification of Scope 1 and Scope 2 data by the Japan Quality Assurance Organization (JQA).

## 3. Emission Reduction Targets

In order to make progress towards Net Zero, Nipro Medical Europe has adopted the following carbon reduction targets, consistent with the Nipro Group's global sustainability strategy and aligned with the Science Based Targets initiative (SBTi) methodology.

Target Year	Scope	Target Description	Reduction vs. 2021 Baseline
2025	1 & 2	Interim milestone: energy efficiency, renewable electricity procurement, fleet transition	~4%
2030	1 & 2	Absolute reduction through renewables, electrification of fleet, efficiency projects	~42%
2030	3	Scope 3 screening completed; supplier engagement programme launched; SBTi submission initiated	Baseline established
2040	1 & 2	Carbon neutrality in own operations (Nipro Group target for Scopes 1 & 2)	~95% + max 5% offsets



2045	1, 2 & 3	Net Zero Scope 1 & 2; 80% Scope 3 reduction (Nipro Group long-term target)	Net Zero (S1+S2); -80% (S3)
2050	1, 2 & 3	Net Zero across the full value chain, aligned with UK Government and NHS targets	100% (net)

## 4. Carbon Reduction Projects

### 4.1. Completed actions

- Renewable electricity (solar): Installation of 100 solar panels with a production potential of 30.06 MWh/year, delivering an estimated annual CO<sub>2</sub>e reduction of approximately 21.4 tonnes.
- Energy management system: Implementation of an ISO 14001-aligned environmental management system with annual review cycles, ambitious environmental objectives, and continual improvement obligations.
- LED lighting transition: Replacement of legacy lighting with LED technology across office and operational areas, reducing electricity demand and associated Scope 2 emissions.
- Fleet electrification: Transition of company vehicles to electric and hybrid alternatives. Petrol and diesel options removed from the company car policy for new leases.
- Packaging waste reduction: Light weight secondary packaging materials.
- Scope 3 data baseline: Completion of initial Scope 3 screening across all relevant categories using spend-based methodology, establishing the baseline for future target-setting and action planning.
- EcoVadis / CDP participation: Annual participation in EcoVadis assessments and CDP disclosure at group level, supporting transparent third-party benchmarking

### 4.2. Planned and Ongoing actions

Scope / Area	Action
Scope 1	Heat pump installation to replace gas-fired heating systems
Scope 1	Continued fleet transition: 100% zero-emission company cars by 2030
Scope 1	Introduction of low-pressure compressed-air systems to reduce energy intensity
Scope 2	Accelerate procurement of renewable electricity (100% REGO-backed tariff target)
Scope 2	Full commissioning of process wastewater heat-recovery system
Scope 2	Evaluation and installation of additional on-site photovoltaic capacity
Scope 2	Upgrade Building Management Systems (BMS) for optimised HVAC control



Scope 3	Logistics optimisation: container fill rates, route optimisation, modal shift (Cat. 4 & 9)
Scope 3	Supply chain engagement: supplier engagement supplier (Cat. 1)
Scope 3	Product Life Cycle Assessment (LCA) expansion across portfolio (Cat. 1, 11, 12)
Scope 3	Transition from spend-based to activity-based accounting for key Scope 3 categories
Scope 3	Zero waste to landfill: comprehensive on-site waste management maintained (Cat. 5)
Scope 3	Business travel reduction: video-conferencing promotion, remote-work policy (Cat. 6)
Scope 3	Migration to cloud-based IT systems (Cat. 3 & indirect Scope 2 reduction)
Governance	Annual CRP review, update, and public republication with refreshed Scope 1-3 data
Governance	Employee sustainability training programme and internal champions network

## 5. Declaration and sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 006 and associated guidance and the reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol Corporate Standard ([ghgprotocol.org/corporate-standard](https://ghgprotocol.org/corporate-standard)).

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard ([ghgprotocol.org/standards/scope-3-standard](https://ghgprotocol.org/standards/scope-3-standard)).

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body) of Nipro Medical Europe NV.

<b>Signed on behalf of Nipro Medical Europe NV:</b>	
<b>Name:</b>	Serge Kemps
<b>Position:</b>	CEO
<b>Date:</b>	26/02/2026